Key result
Early FH diagnosis and risk stratification enable individualized lipid-lowering therapy to prevent CAD.
Why the study?
Familial hypercholesterolemia carries a high risk of cardiovascular disease, yet phenotype severity varies significantly even within this monogenic disorder. Understanding the inherited and acquired factors contributing to these differences is needed to guide individualized lipid-modification therapies.
Answers are grounded in this paper and cite their sources.
This narrative review highlights the necessity of early diagnosis (prior to Achilles tendon thickening), comprehensive genetic testing, and subclinical plaque imaging to tailor lipid-lowering therapy intensity to individual cardiovascular risk in familial hypercholesterolemia.
Familial hypercholesterolemia (FH) is one of the most common and, therefore, important inherited disorders in preventive cardiology. This disease is mainly caused by a single pathogenic mutation in the low-density lipoprotein receptor or its associated genes. Moreover, it is correlated with a high risk of cardiovascular disease. However, the phenotype severity even in this monogenic disease significantly varies. Thus, the current study aimed to describe FH and its importance and the factors (inherited and acquired) contributing to differences in phenotype severity. Different lipid-modification therapies according to these factors can lead to individualized treatments, which are also essential in the general populations.
No takes yet. Share an insight, caveat, or question.
Tada et al. (2022) conducted a review in Familial hypercholesterolemia (FH). Individualized lipid-modification therapy (including statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, lomitapide, evinacumab, and LDL apheresis) guided by genetic and clinical risk stratification was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: